Evoke Pharma: Funding, Investors & Team (Oct 2026)
Evoke Pharma, Inc. is a privately held specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve known products and its focused physician base. Despite the relatively high number of patients suffering from gastrointestinal diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. These physicians conduct over 31 million patient visits and write almost 40 million prescriptions each year valued at $4.8 billion. Also, GI diseases may limit or alter the effectiveness of traditional oral therapies due to the disease for which the product is intended to treat. By developing enhanced versions of currently approved drug products, through novel delivery formats or formulations, Evoke intends to provide patients additional treatment options. Evoke's lead product candidate, EVK-001, is in late stage clinical testing. The company has exclusive rights to a novel formulation and delivery of a currently marketed GI product. The product is intended for the treatment of diabetic gastroparesis. Evoke has advanced its product development activities by leveraging several corporate relationships with many external clinical, CMC, and regulatory experts. Evoke plans to continue this strategy of developing acquired products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.
Evoke Pharma has raised $7.5M across 1 funding round on record, the most recent an undisclosed round of $7.5M announced in Feb 2024.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Evoke Pharma Company Profile and Key Stats
Latest funding round on record: Feb 2024.
Evoke Pharma Funding Rounds
Evoke Pharma Founders and Leadership Team
Contact details for the Evoke Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Evoke Pharma Funding Compared to Other Biotechnology Startups
Evoke Pharma's latest round of $7.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evoke Pharma in Biotechnology and San Diego
Companies Similar to Evoke Pharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Evoke Pharma Funding FAQs
What does Evoke Pharma do?
Evoke Pharma, Inc. is a privately held specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve known products and its focused physician base. Despite the relatively high number of patients suffering from gastrointestinal diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. These physicians conduct over 31 million patient visits and write almost 40 million prescriptions each year valued at $4.8 billion. Also, GI diseases may limit or alter the effectiveness of traditional oral therapies due to the disease for which the product is intended to treat. By developing enhanced versions of currently approved drug products, through novel delivery formats or formulations, Evoke intends to provide patients additional treatment options. Evoke's lead product candidate, EVK-001, is in late stage clinical testing. The company has exclusive rights to a novel formulation and delivery of a currently marketed GI product. The product is intended for the treatment of diabetic gastroparesis. Evoke has advanced its product development activities by leveraging several corporate relationships with many external clinical, CMC, and regulatory experts. Evoke plans to continue this strategy of developing acquired products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.
How much funding has Evoke Pharma raised?
Evoke Pharma has raised $7.5M across 1 round on record. The most recent is an undisclosed round of $7.5M announced in Feb 2024.
When did Evoke Pharma last raise funding?
Evoke Pharma's most recent funding round on record is an undisclosed round of $7.5M, announced in Feb 2024.
Who founded Evoke Pharma?
FundedIQ lists Matthew J Donofrio (Founder) at Evoke Pharma.
Where is Evoke Pharma headquartered?
Evoke Pharma is based in San Diego, California, United States.
How many employees does Evoke Pharma have?
Evoke Pharma is in the 11-50 employee band.
How does Evoke Pharma's funding compare to other Biotechnology startups?
Evoke Pharma's latest round of $7.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Evoke Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evoke Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.